bausch  lomb corporation blco has acquired johnson  johnsons jnj eye and contact lens drops brand blink for 1065 million to bolster its position in overthecounter otc consumer products for eye care the deal marks its second in two weeks to bolster the contact lens makers portfolio of eye care products the blink portfolio of eye drops consists of various eye drops and contact lens rewetting drops that provide immediate and longlasting symptom relief according to a 2022 gallup study 57 of american adults report eye dryness and nearly half 48 use otc lubricant drops for relief also read inflationary factors and slow product uptake could be headwinds for bausch  lomb analyst says last week bausch  lomb struck a 175 billion deal with swiss drugmaker novartis ag nvs to buy several eyecare products including antiinflammation eye drop xiidra in may the fda approved bausch  lombs miebo for dryeye condition which affects about 739 million people worldwide including around 38 million in the united states reuters reported the report citing morningstar analyst added that the global dry eye disease market is expected to be worth around 5 billion price action blco shares are down 142 at 1950 on the last check thursday